Navigation Links
CMAJ calls on federal government to protect Canadians from unsafe drugs

OTTAWA, ONTARIO, CANADA Canada needs to modernize its pharmaceutical drug laws to ensure that new drugs as well as older drugs are safe for Canadians, states an editorial in CMAJ (Canadian Medical Association Journal)

"Canadians are left inadequately protected by a federal Food and Drugs Act that's a dusty relic, virtually untouched since 1953," writes Dr. Paul Hbert, Editor-in-Chief, with coauthors. "This leaves Health Canada with the Herculean task of ensuring that both old and new medications are as safe as they are effective without the powers, regulatory tools or resources to do so."

New drugs are often released based on scant understanding of the safety of the drug compounds, which can cause serious health effects and even death, as the examples of rofecoxib (Vioxx) for arthritis, rosiglitazone (Avandia) for diabetes and tegaserod (Zelnorm) for irritable bowel syndrome show.

"The federal election offers a chance to spur government action, or at least extract promises from federal parties, to create a food and drug act that will do everything possible to ensure medications, new and old, are safe and effective," state the authors.

Reform includes increasing the level of evidence gathering to support the safety of a drug, increased monitoring after release of a drug, progressive licensing and modernizing legislation to bring it to similar standards in the United States and the European Union.


Contact: Kim Barnhardt
613-520-7116 x2224
Canadian Medical Association Journal

Page: 1

Related medicine news :

1. Report Blames Speedy FDA Clearance for Medical Device Recalls
2. Calls Go Out to Revive the Traditional Physical
3. Tufts University calls for moderate approach to teaching personalized genomic testing
4. FDA Panel Calls for Safety Review of Mercury in Dental Fillings
5. FDA Calls for New Warnings on Some Prostate Cancer Drugs
6. International Menopause Society calls upon medical community to improve the vaginal health of postmenopausal women
7. European Nurse Society calls to action on breakthrough cancer pain
8. Prostate cancer community calls for better early detection and treatment
9. IAS calls for an end to harassment, intimidation and imprisonment of HIV professionals
10. FDA Chief Says More Egg Recalls Possible
11. Virtual mates reveal role of romance in parrot calls
Post Your Comments:
(Date:12/1/2015)... ... 2015 , ... CloudLIMS today announced that it is the ... the New Products and Services category for its innovative product offering, BioTracer. ... that helps labs organize data and track samples with storage inventories. BioTracer's SaaS ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... must mark the film for accurate interpretation by the radiologist. The marking utensils ... inventor from Sacramento, Calif., has found a way to alleviate this problem. , ...
(Date:12/1/2015)... ... 2015 , ... McLean, VA., December 1, 2015 - Octo ... sprint agile development contract to support the National Geospatial-Intelligence Agency's (NGA) IT Services ... engineering, infrastructure, as well as operations and sustainment support to the NGA’s Agile ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani as ... Cisco Unified Contact Center solutions targeted to the high-end enterprise contact center marketplace. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 Russia has always ... 70% of new drugs registered in Europe in ... --> Russia has always been a country ... drugs registered in Europe in 2015 were tested ... Russia has always been a country of choice ...
(Date:12/1/2015)... Dec. 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... chronic pain, announced today that the company will present at ... December 1-3 at the Luxe Sunset Boulevard Hotel in ... CEO of Relmada Therapeutics, will present on Thursday, December 3, ... . Please register at least 10 minutes prior ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology: